Literature DB >> 17953723

Issues concerning the use of hormone replacement therapy and risk of fracture: a population-based, nested case-control study.

Giovanni Corrao1, Antonella Zambon, Federica Nicotra, Valentino Conti, Rossella E Nappi, Luca Merlino.   

Abstract

AIMS: To investigate the effect of duration, how recently it has been used, and age at start of hormone replacement therapy (HRT) and the risk of bone fracture.
METHODS: A population-based, nested case-control study was conducted in Lombardia, Northern Italy. The 78,294 women aged 45-75 years who received at least one HRT prescription during 1998-2000 were followed until 2005. Cases were women who experienced bone fracture during follow-up. Up to six controls were randomly selected for each case from the cohort after matching for age and date of cohort entry. The odds ratio of fracture associated with the use of HRT was estimated by conditional logistic regression.
RESULTS: One thousand one hundred and seventy-four cases and 6760 controls were included. Compared with women who took HRT for less than 2 months, those who were treated for more than 20 months had an odds ratio (OR) of 0.80 (95% confidence interval 0.65, 0.99). This risk reduction was still significant among current HRT users (OR 0.71, 95% CI 0.55, 0.90) and in women who began therapy at the age of 55-65 years (OR 0.63, 95% CI 0.42, 0.94) or 65-75 years (OR 0.56, 95% CI 0.32, 0.99). There was no statistical evidence of a protective effect for women who had stopped treatment more than 6 months previously or those who began HRT at the age of 45-55 years.
CONCLUSIONS: HRT should be continued for long periods to achieve an optimal protection from fracture. The fracture reducing potential of HRT seems to disappear after a few months without treatment and might mainly act in women who begin therapy at older age.

Entities:  

Mesh:

Year:  2007        PMID: 17953723      PMCID: PMC2291264          DOI: 10.1111/j.1365-2125.2007.02904.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  36 in total

1.  17beta-estradiol (1 mg/day) continuously combined with dydrogesterone (5, 10 or 20 mg/day) increases bone mineral density in postmenopausal women.

Authors:  J C Stevenson; P Teter; B Lees
Journal:  Maturitas       Date:  2001-04-20       Impact factor: 4.342

Review 2.  Hormone therapy to prevent disease and prolong life in postmenopausal women.

Authors:  D Grady; S M Rubin; D B Petitti; C S Fox; D Black; B Ettinger; V L Ernster; S R Cummings
Journal:  Ann Intern Med       Date:  1992-12-15       Impact factor: 25.391

Review 3.  Heterogeneity of age-related fractures: implications for epidemiology.

Authors:  L J Melton; S R Cummings
Journal:  Bone Miner       Date:  1987-07

4.  Results from the Estonian postmenopausal hormone therapy trial [ISRCTN35338757].

Authors:  Piret Veerus; Sirpa-Liisa Hovi; Krista Fischer; Mati Rahu; Matti Hakama; Elina Hemminki
Journal:  Maturitas       Date:  2006-02-28       Impact factor: 4.342

5.  Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen/progestin interventions (PEPI) trial. The Writing Group for the PEPI.

Authors: 
Journal:  JAMA       Date:  1996-11-06       Impact factor: 56.272

6.  Hormonal replacement therapy reduces forearm fracture incidence in recent postmenopausal women - results of the Danish Osteoporosis Prevention Study.

Authors:  L Mosekilde; H Beck-Nielsen; O H Sørensen; S P Nielsen; P Charles; P Vestergaard; A P Hermann; J Gram; T B Hansen; B Abrahamsen; E N Ebbesen; L Stilgren; L B Jensen; C Brot; B Hansen; C L Tofteng; P Eiken; N Kolthoff
Journal:  Maturitas       Date:  2000-10-31       Impact factor: 4.342

7.  Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women.

Authors:  Robert Lindsay; J Christopher Gallagher; Michael Kleerekoper; James H Pickar
Journal:  JAMA       Date:  2002 May 22-29       Impact factor: 56.272

8.  Bone mass and its relationship to age and the menopause.

Authors:  L Nilas; C Christiansen
Journal:  J Clin Endocrinol Metab       Date:  1987-10       Impact factor: 5.958

9.  Hip fracture and the use of estrogens in postmenopausal women. The Framingham Study.

Authors:  D P Kiel; D T Felson; J J Anderson; P W Wilson; M A Moskowitz
Journal:  N Engl J Med       Date:  1987-11-05       Impact factor: 91.245

10.  Evidence for efficacy of drugs affecting bone metabolism in preventing hip fracture.

Authors:  J A Kanis; O Johnell; B Gullberg; E Allander; G Dilşen; C Gennari; A A Lopes Vaz; G P Lyritis; G Mazzuoli; L Miravet
Journal:  BMJ       Date:  1992-11-07
View more
  2 in total

1.  Effectiveness of adjuvanted influenza vaccination in elderly subjects in northern Italy.

Authors:  Salvatore Mannino; Marco Villa; Giovanni Apolone; Noel S Weiss; Nicola Groth; Ivana Aquino; Liana Boldori; Fausta Caramaschi; Antonio Gattinoni; Giancarlo Malchiodi; Kenneth J Rothman
Journal:  Am J Epidemiol       Date:  2012-08-31       Impact factor: 4.897

2.  Lower risk of hip fractures among Swedish women with large hips?

Authors:  S Klingberg; K Mehlig; V Sundh; B L Heitmann; L Lissner
Journal:  Osteoporos Int       Date:  2018-01-27       Impact factor: 4.507

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.